Sector News

Generics set to undercut blockbusters from Merck, Novartis and BMS

January 17, 2017
Life sciences

Several blockbusters are set to take a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharma companies.

Dickson Data has compiled a list of major drugs losing their IP protection this year, and standing at the top is Novartis’ Sandostatin LAR with $1.6 billion in annual sales. Used to treat acromegaly and severe diarrhea and flushing associated with carcinoid syndrome, the drug will quickly face generic erosion from a slew of companies, including Teva, Sun Pharma, Sagent Pharmaceuticals and Wockhardt.

Behind Sandostatin LAR is Merck’s antibiotic Cubicin, a key prize in the New Jersey pharma giant’s $9.5 billion purchase of Cubist Pharmaceuticals back in 2014. The drug currently tallies $1.17 billion in sales, according to Dickson, and is set to face cheaper rivals from Hospira, Teva and Crane Pharma, FDA records show.

Merck faces another blockbuster loss, too: Its cholesterol med Vytorin, with $1.12 billion in sales, comes in fourth place, according to Dickson. Bristol-Myers’ HIV drug Reyataz stands in third place with $1.14 billion.

Branded drugs tend to lose 90% of their sales after multiple generics make it to market, according to the firm. The copycats are typically 80 to 85% cheaper than the branded originals.

Although not a blockbuster like others on the list, Eli Lilly’s ADHD med Strattera rounds out the top five drugs facing a patent expiration, Dickson found, with annual sales just shy of $700 million. Zydus, Aurobindo, Sun Pharma and Mylan are among the companies seeking to grab a piece of that drug’s annual haul.

Merck’s antibiotic Invanz and antifungal med Cancidas are also set to lose patent protection for the New Jersey pharma giant; all told, the drugmaker has four meds totaling $3.8 billion in sales—10% of its total haul—susceptible to generics this year.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”